Elm Partners Management LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,008 shares of the biopharmaceutical company’s stock, valued at approximately $798,000.
Several other hedge funds also recently bought and sold shares of ALNY. Groupama Asset Managment grew its position in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Norges Bank bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $895,816,000. Arrowstreet Capital Limited Partnership grew its position in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $369,943,000. Finally, AQR Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after buying an additional 555,759 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.
Insider Activity at Alnylam Pharmaceuticals
In related news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Pushkal Garg sold 1,775 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares in the company, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,337 shares of company stock valued at $2,370,087 over the last quarter. 0.86% of the stock is owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Price Performance
Shares of ALNY stock opened at $301.98 on Monday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.28 and a 1-year high of $495.55. The stock’s 50-day moving average is $309.38 and its 200 day moving average is $354.12. The company has a market cap of $40.32 billion, a P/E ratio of 82.51 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the company earned ($0.44) earnings per share. The firm’s revenue for the quarter was up 96.4% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Read More
- Five stocks we like better than Alnylam Pharmaceuticals
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
